United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of May, 2018

 

Commission File Number: 001-35892

 

 

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

 

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

1.          Details of the person discharging managerial responsibilities / person closely associated
a.          Name Volker Knappertz
2.          Reason for the notification
a.          Position/status Chief Medical Officer
b.         

Initial notification

/Amendment

Initial notification
3.          Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.          Name GW Pharmaceuticals PLC
b.          LEI  
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

Financial instrument, type of instrument

Identification code

 

American Depositary Shares

ISIN: 36197T1034

b.          Nature of the transaction Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 1,012 American Depositary Shares (ADSs) followed by sale of 331 ADSs to cover tax liability. Remaining 681 ADSs have been retained.
c.          Price(s) and volume(s)

Price(s)

 $153.63

Volume(s)

331  

 

ADS’s sold

d.         

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.          Date of the transaction May 18, 2018
f.          Place of the transaction Nasdaq, New York

 

 

 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

1.          Details of the person discharging managerial responsibilities / person closely associated
a.          Name Scott Giacobello
2.          Reason for the notification
a.          Position/status Chief Financial Officer
b.         

Initial notification

/Amendment

Initial notification
3.          Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.          Name GW Pharmaceuticals PLC
b.          LEI  
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

Financial instrument, type of instrument

Identification code

 

American Depositary Shares

ISIN: 36197T1034

b.          Nature of the transaction Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 678 American Depositary Shares (ADSs) followed by sale of 231 ADSs to cover tax liability. Remaining 447 ADSs have been retained.
c.          Price(s) and volume(s)

Price(s)

 $153.51

Volume(s)

231  

 

ADS’s sold

d.         

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.          Date of the transaction May 18, 2018
f.          Place of the transaction Nasdaq, New York

  

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name: Adam George
  Title: Secretary
     
Date: May 24, 2018    

 

 

 

 

 

Ways to keep up to date with GW